摘要
整合素受体被认为是致癌的关键因素。αIIbβ3-整合素(GP IIb/IIIa)是血小板表面的主要糖蛋白,它也存在于某些癌细胞系中。其作用于肿瘤细胞的分子机制尚不清楚。本研究提出了两个αIIbβ3-整合素:阿昔单抗和依替巴肽对细胞凋亡的影响,如在MCF-7乳腺癌细胞中对脯氨酸氧化酶(POX)的表达,信号分子ERK 1 / 2,转录因子NF-κB和HIF-1κα,血管内皮生长因子(VEGF)以及DNA的生物合成,的胶原的生物合成和脯氨酸肽酶活性等影响。配体诱导的细胞凋亡,但我们在测试不同αIIbβ3-整合素时发现其分子作用机制存在显著差异。这些差异包括POX, HIF-1α, NF-κB,VEGF的表达,血管内皮生长因子和胶原的生物合成。依替巴肽使MCF-7细胞凋亡的活性比阿昔单抗更强。这项研究的结果表明,依替巴肽可以被认为是一个新的抗癌治疗药物。
关键词: αIIbβ3-整合素,αIIbβ3-整合素,阿昔单抗,依替巴肽,MCF-7乳腺癌细胞,细胞凋亡
图形摘要
Current Drug Targets
Title:αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells
Volume: 16 Issue: 13
Author(s): Joanna Kononczuk, Arkadiusz Surazynski, Urszula Czyzewska, Izabela Prokop, Michal Tomczyk, Jerzy Palka and Wojciech Miltyk
Affiliation:
关键词: αIIbβ3-整合素,αIIbβ3-整合素,阿昔单抗,依替巴肽,MCF-7乳腺癌细胞,细胞凋亡
摘要: Integrin receptors are considered to be the key factors in carcinogenesis. αIIbβ3-Integrin (GP IIb/IIIa) is the main glycoprotein of the surface of platelets, its presence has also been noted on the certain cancer cell lines. The molecular mechanism of its action in cancer cells remains unknown. This study presents effects of two αIIbβ3-inhibitors: Abciximab and Eptifibatide on apoptosis, expression of proline oxidase (POX), signaling molecules ERK 1/2, transcription factor NF-κB and HIF-1α, vascular endothelial growth factor (VEGF) as well as DNA biosynthesis, collagen biosynthesis and prolidase activity in MCF-7 breast cancer cells. Both ligands induced apoptosis, however we found significant differences in molecular mechanism of action between tested αIIbβ3-inhibitors. These differences include expression of POX, HIF-1α, NF-κB,VEGF and collagen biosynthesis. Eptifibatide presented stronger proapoptotic activity in MCF-7 cells than Abciximab. Results of this study suggest that Eptifibatide may be considered as a novel candidate for development of new anticancer therapy.
Export Options
About this article
Cite this article as:
Joanna Kononczuk, Arkadiusz Surazynski, Urszula Czyzewska, Izabela Prokop, Michal Tomczyk, Jerzy Palka and Wojciech Miltyk , αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells, Current Drug Targets 2015; 16 (13) . https://dx.doi.org/10.2174/1389450115666140804220441
DOI https://dx.doi.org/10.2174/1389450115666140804220441 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin D and Cystic Fibrosis Lung Disease
Mini-Reviews in Medicinal Chemistry Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: Targeted Cancer Therapies: Current Status and Future Directions (Guest Editors: Ioannis Starakis)]
Current Medicinal Chemistry FoxO Proteins: Regulation and Molecular Targets in Liver Cancer
Current Medicinal Chemistry Hemangiomas, Angiosarcomas, and Vascular Malformations Represent the Signaling Abnormalities of Pathogenic Angiogenesis
Current Molecular Medicine Fundamental Concepts of the Angiogenic Process
Current Molecular Medicine Molecular Mechanisms, Proteinopathies and Therapeutic Strategies in Neurodegenerative Disorders
Current Genomics FAK and Nanog Cross Talk with p53 in Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Role of Amygdalin in Blocking DNA Replication in Breast Cancer In Vitro
Current Pharmaceutical Biotechnology Effect of Vitamin D<sub>3</sub> on Lifespan in Caenorhabditis elegans
Current Aging Science Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets Comparative Studies of the Chromogranin A-Derived Neuropeptide WE-14
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis
Current Drug Targets Implication of Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegenerative Disorders – Contemporary Approaches
CNS & Neurological Disorders - Drug Targets Molecular Testing and Personalized Treatment of Lung Cancer
Current Molecular Pharmacology Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature
Current Drug Metabolism Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Strategic Aspects of NPY-Based Monoclonal Antibodies for Diagnosis and Treatment of Breast Cancer
Current Protein & Peptide Science Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples
Recent Patents on Biomarkers